In an effort to elevate healthcare in India, Siemens Healthineers has begun local manufacturing of Atellica chemistry reagents at its Vadodara facility, a milestone for the Make in India initiative that will benefit patients and healthcare professionals across the country.

These chemistry reagents are used in routine blood tests that detect conditions such as infections, diabetes, and organ function abnormalities. Local production aims to strengthen better access to quality care for patients and supports early detection and preventive care, enabling clinicians to monitor risk factors in time.

“Bringing the expertise and legacy of over 50 years, our Vadodara facility will play a pivotal role in producing diagnostic solutions tailored to the needs of Indian laboratories and healthcare providers. This move also aligns with national priorities to boost domestic manufacturing in critical healthcare segments, advancing preventive healthcare and contributing to India’s vision of self reliance in healthcare technologies.”-Hariharan Subramanian, Managing Director, Siemens Healthcare Pvt Ltd.

The Atellica Solution is widely recognized for its innovation, sustainability and efficiency in laboratory diagnostics, and the availability of locally manufactured reagents will further strengthen its value for healthcare providers and patients in India.

Media contact

Pranav Patil

pranav.patil@siemens-healthineers.com   

Ojashwi Singh

ojashwi.singh@siemens-healthineers.com   

Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2025, which ended on September 30, 2025, Siemens Healthineers had approximately 74,000 employees worldwide and generated revenue of around €23.4 billion. Further information is available at siemens-healthineers.com.

Siemens Healthineers in India has a countrywide sales network and round the clock service set up, two manufacturing facilities at Vadodara for Diagnostics and at Bengaluru for Medical Imaging Products, backed by a state-of the art R&D center as well as a global software development center at Bengaluru. With over 7000 employees across the nation, we are playing a significant role in transforming care delivery in India and supporting healthcare providers across the entire range of patient care  from prevention and early detection to diagnosis and on to treatment and aftercare. Further information is available at www.siemens-healthineers.co.in